These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

819 related items for PubMed ID: 1330300

  • 1. T cell recognition of Epstein-Barr virus associated lymphomas.
    Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG.
    Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
    Hamilton-Dutoit SJ, Rea D, Raphael M, Sandvej K, Delecluse HJ, Gisselbrecht C, Marelle L, van Krieken HJ, Pallesen G.
    Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
    [Abstract] [Full Text] [Related]

  • 3. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB.
    J Immunol; 1997 Apr 01; 158(7):3325-34. PubMed ID: 9120290
    [Abstract] [Full Text] [Related]

  • 4. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
    Dolcetti R, Frisan T, Sjöberg J, De Campos-Lima PO, Pisa P, De Re V, Gloghini A, Rizzo S, Masucci MG, Boiocchi M.
    Cancer Res; 1995 Aug 15; 55(16):3675-81. PubMed ID: 7627978
    [Abstract] [Full Text] [Related]

  • 5. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
    Khanna R, Burrows SR, Suhrbier A, Jacob CA, Griffin H, Misko IS, Sculley TB, Rowe M, Rickinson AB, Moss DJ.
    J Immunol; 1993 Jun 01; 150(11):5154-62. PubMed ID: 7684421
    [Abstract] [Full Text] [Related]

  • 6. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG, Zhang QJ, Gavioli R, De Campos-Lima PO, Murray RJ, Brooks J, Griffin H, Ploegh H, Rickinson AB.
    Int Immunol; 1992 Nov 01; 4(11):1283-92. PubMed ID: 1282031
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus infection and associated products (LMP, EBNA2, vIL-10) in nodal non-Hodgkin's lymphoma of human immunodeficiency virus-negative Japanese.
    Ohshima K, Suzumiya J, Tasiro K, Mukai Y, Tanaka T, Kato A, Kikuchi M.
    Am J Hematol; 1996 May 01; 52(1):21-8. PubMed ID: 8638607
    [Abstract] [Full Text] [Related]

  • 8. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
    Griffin H, Rowe M, Murray R, Brooks J, Rickinson A.
    Eur J Immunol; 1992 Jul 01; 22(7):1741-8. PubMed ID: 1378014
    [Abstract] [Full Text] [Related]

  • 9. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
    Blaschke S, Hannig H, Buske C, Kaup FJ, Hunsmann G, Bodemer W.
    J Med Virol; 2001 Sep 01; 65(1):114-20. PubMed ID: 11505452
    [Abstract] [Full Text] [Related]

  • 10. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
    Gregory CD, Rowe M, Rickinson AB.
    J Gen Virol; 1990 Jul 01; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
    [Abstract] [Full Text] [Related]

  • 11. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
    Kis LL, Takahara M, Nagy N, Klein G, Klein E.
    Immunol Lett; 2006 Apr 15; 104(1-2):83-8. PubMed ID: 16386314
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line.
    Zhang Q, Brooks L, Busson P, Wang F, Charron D, Kieff E, Rickinson AB, Tursz T.
    Eur J Immunol; 1994 Jun 15; 24(6):1467-70. PubMed ID: 8206105
    [Abstract] [Full Text] [Related]

  • 13. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB.
    J Exp Med; 1992 Jul 01; 176(1):157-68. PubMed ID: 1319456
    [Abstract] [Full Text] [Related]

  • 14. Epstein-Barr virus, lymphomas and Hodgkin's disease.
    Young LS, Rowe M.
    Semin Cancer Biol; 1992 Oct 01; 3(5):273-84. PubMed ID: 1335791
    [Abstract] [Full Text] [Related]

  • 15. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH, Wolf H, Minarovits J.
    Autoimmunity; 2008 May 01; 41(4):298-328. PubMed ID: 18432410
    [Abstract] [Full Text] [Related]

  • 16. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
    Callahan J, Pai S, Cotter M, Robertson ES.
    Virology; 1999 Sep 15; 262(1):18-30. PubMed ID: 10489337
    [Abstract] [Full Text] [Related]

  • 17. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis.
    Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, Rickinson AB.
    Nature; 1991 Feb 14; 349(6310):612-4. PubMed ID: 1705663
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT, Fernandes BJ, Mock D.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug 14; 92(2):184-93. PubMed ID: 11505266
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP.
    Cancer Res; 2001 Aug 15; 61(16):6219-26. PubMed ID: 11507075
    [Abstract] [Full Text] [Related]

  • 20. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.
    Eur J Immunol; 2006 Mar 15; 36(3):593-602. PubMed ID: 16479544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.